On Tuesday, in the course of current trade, Shares of Transocean Ltd. (NYSE:RIG), gained 3.83%, and is now trading at $20.32.
Transocean, stated a net loss attributable to controlling interest for the three months ended March 31, 2015 of $483 million, or $1.33 per diluted share. First quarter 2015 results comprised of net unfavorable items of $881 million, $2.43 per diluted share, as follows:
- $481 million, or $1.34 per diluted share, associated with an impairment of the Deepwater Floater asset group;
- As formerly declared, $393 million, or $1.07 per diluted share, in impairments of assets classified as held for sale;
- $5 million, or $0.01 per diluted share, in costs related to one-time termination benefits; and
- $2 million, or $0.01 per diluted share, primarily associated with suspended operations and other items.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services. As of February 17, 2015, it owned or had partial ownership interests in, and operated 71 mobile offshore drilling units that comprise of 44 high-specification floaters, 17 midwater floaters, and 10 high-specification jackups.
During an Afternoon trade, Shares of Baxter International Inc. (NYSE:BAX), dipped -0.46%, and is now trading at $68.95.
Baxter International, declared plans to host its 2015 Investor Conferences in advance of the company’s separation into two leading global healthcare companies. The Investor Conference for Baxter International Inc. will be held on Monday, May 18, from 12:30 p.m. to 5:00 p.m. EDT. The conference for Baxalta Incorporated will be held on Tuesday, May 19, from 8:00 a.m. to 1:00 p.m. EDT. Both conferences will be held at The Plaza Hotel in New York City.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
Shares of Accenture plc (NYSE:ACN), during its Tuesday’s current trading session fell -0.87%, and is now trading at $95.17.
Nearly nine in 10 financial services firms plan to enhance their investment in risk-administration capabilities in the next two years in response to emerging risks of cyber security and fraud, according to a new report from Accenture.
The Accenture 2015 Global Risk Administration Study – based on a survey of more than 450 senior risk-administration executives in the banking, capital markets and insurance industries – found that 86 percent of respondents said their organizations plan to enhance their investment in risk-administration capabilities in the next two years, with one in four (26 percent) planning to enhance it by more than 20 percent. In addition, three in 10 respondents (29 percent) said their companies plan to enhance by more than 20 percent their investment in Cloud/Software-as-a-Service (SaaS) and big data and analytics.
The report found clear evidence of the increasing impact that cyber security and fraud is having on financial services firms’ business and the risk-administration function in particular. For instance:
- More than one-third (34 percent) of respondents said that understanding cyber risk will be the most-needed capability in their risk function.
- Nearly two-thirds (65 percent) of respondents said that cyber/IT risk will have an raised impact on their business in the next two years, with 26 percent saying that the enhance would be significant.
- More than eight in 10 respondents (82%) said that emerging risks, such as cyber and social media, account for more of the chief risk officer’s (CRO) time than ever before.
Accenture plc provides administration consulting, technology, and business process outsourcing services worldwide. The company’s Communications, Media & Technology segment offers enterprise and industry-customized services in network engineering and integration, field force enablement, and IP network migration; provides online customer and enterprise relationship administration services; and assists customers in developing video-over-IP platforms, and transforming legacy broadcast platforms to digital.
Finally, Opko Health, Inc. (NYSE:OPK), gained 2.88% Tuesday.
OPKO Health, stated operating and financial results for its first quarter ended March 31, 2015.
Business Highlights
- Pfizer Partnership Agreement for Long Acting Human Growth Hormone Closed in January 2015; OPKO Received Up-Front Payments Totaling $295 million for Global Commercialization Rights to hGH-CTP: In connection with the collaboration, OPKO received up-front payments of $295 million and will receive an additional $275 million upon achievement of development-related milestones. In addition, OPKO will receive initial royalty payments upon the commercialization of hGH-CTP for Adult growth hormone deficiency (GHD). Upon the launch of hGH-CTP for Pediatric GHD, the royalties will transition to gross profit sharing among all indications for both hGH-CTP and Pfizer’s Genotropin®. OPKO will lead clinical development and will be responsible for funding the development programs for Adult and Pediatric GHD and growth failure in children born small for gestational age (SGA). Pfizer will be responsible for all development costs for additional indications in addition to all post-marketing studies. In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan.
- hGH-CTP for Pediatric GHD Data Presented at 2015 ENDO; Adult Phase 3 Clinical Trial Continues to Advance: OPKO presented positive twelve-month data from its ongoing Phase 2 clinical trial for pediatric GHD at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 5th, 2015 in San Diego, California.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
